Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Polyrizon (PLRZ) previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback